Compare PNTG & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | NNNN |
|---|---|---|
| Founded | 2019 | 2021 |
| Country | United States | Germany |
| Employees | N/A | 27 |
| Industry | Medical/Nursing Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 417.8M |
| IPO Year | 2019 | N/A |
| Metric | PNTG | NNNN |
|---|---|---|
| Price | $41.95 | $10.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $37.00 | N/A |
| AVG Volume (30 Days) | ★ 283.7K | 28.7K |
| Earning Date | 05-05-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $947,705,000.00 | N/A |
| Revenue This Year | $24.72 | N/A |
| Revenue Next Year | $7.61 | N/A |
| P/E Ratio | ★ $172.25 | $446.57 |
| Revenue Growth | ★ 36.31 | N/A |
| 52 Week Low | $21.74 | $8.30 |
| 52 Week High | $42.55 | $54.90 |
| Indicator | PNTG | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 67.43 | 32.17 |
| Support Level | $28.05 | $8.30 |
| Resistance Level | $42.55 | $30.21 |
| Average True Range (ATR) | 1.59 | 1.26 |
| MACD | -0.10 | 0.50 |
| Stochastic Oscillator | 84.61 | 42.40 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments; home health and hospice services and senior living services. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).